Navigation Links
German Patient Surpasses 5 Years of Support on DuraHeart™ Left Ventricular Assist Device
Date:7/19/2011

ANN ARBOR, Mich., July 19, 2011 /PRNewswire/ -- Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, today announced that a patient implanted with the DuraHeart™ Left Ventricular Assist System (LVAS) has surpassed five years of support on the mechanical circulatory support device.  Helga Gieseke, living in Germany, was treated at The Deutsches Herzzentrum Berlin (DHZB, German Heart Institute Berlin) and is now one of the longest-living heart failure recipients of the DuraHeart™ LVAS device.  

"Now I can breathe again...for years before I received the DuraHeart I was unable to do anything with my children or grandchildren. Since the DuraHeart, I was able to experience the birth of my little grandchild...I can now do things like walk and play catch and am able to participate in the lives of my family."

Mrs. Gieseke's heart problems have been occurring since the 1980's; her first heart surgery was performed in 1994. Between 1994 and 2006, Mrs. Gieseke underwent several procedures including implantation of stents, pacemakers and implantable defibrillators in an attempt to manage her condition. Despite all these treatments, Mrs. Gieseke's condition continued to deteriorate until she found herself unable to walk or carry out simple activities without experiencing chest pain and being short of breath.

Mrs. Gieseke admits that without the DuraHeart, she would probably not have lived to see her most recent birthday. "DuraHeart was my only option; there is a shortage of donor organs, and DuraHeart was my last chance. My family supported my decision {to implant an investigational device} and we have all been extremely happy with the decision and the quality of life the DuraHeart has afforded me."

"It is so gratifying to see patients such as Mrs. Gieseke who have been able to proceed with their lives following the implantation of the DuraHeart LVAS," says President and CEO of Terumo Heart, William Pinon. "Mrs. Gieseke is a prime example of how someone who was in declining health can lead a fulfilling life with end stage heart failure."

The DuraHeart LVAS is the latest-generation rotary blood pump designed for long-term patient support.  The system incorporates a centrifugal flow rotary pump with the magnetically levitated impeller. The pump features three position sensors and electromagnetic coils that suspend the impeller inside the pump chamber without a single contact point. The impeller's active magnetic levitation is designed to eliminate friction by allowing a wide gap between blood contacting surfaces, enabling blood to flow through the pump unimpeded in a smooth, non-turbulent fashion.

The DuraHeart LVAS carries a CE Mark and is currently available for sale in Japan and Europe.  DuraHeart is limited to investigational use only in the United States.  For more information about heart failure, Ventricular Assist Devices or the DuraHeart LVAS, visit www.terumoheart.com.

About Heart Failure

More than 22 million people suffer from heart failure worldwide with approximately one million new patients diagnosed annually. In the setting of an aging global population, heart failure is the number one reason for hospitalization.  The most severely ill patients need heart transplants in order to recover. More than 8,000 people worldwide are on the list of eligible candidates for heart transplants annually, but less than 3,000 receive a transplant each year.  A large number of people who suffer from severe heart failure do not qualify for transplantation due to other health issues. An alternative for these patients is access to artificial mechanical assist.

About Terumo Heart, Inc.

Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan.  The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients.  Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products. DuraHeart is limited to investigational use only in the United States, and is CE marked in Europe.  For more information visit www.terumoheart.com


'/>"/>
SOURCE Terumo Heart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
3. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008
5. STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
6. Award-Winning Medical Technology From Germany
7. BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility
8. Enigma Diagnostics Showcases Its Unique Fully Automated rtPCR Based ML (Mini-Laboratory) Instrument For Point-of-Care Testing at MEDICA 2009 In Dusseldorf, Germany
9. Tekia Enters Into Distribution Agreement With Fritz Ruck/T-MED, Germany to Market Its Accommodative Intraocular Lens to Treat Presbyopia
10. Dune Medical Devices Announces Positive Interim Results From EU MarginProbe™ Study Presented at German Breast Cancer Society Meeting
11. German District Court Finds RENASYS™ GO NPWT System Non-infringing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- According to market research "Global Insulin ... Forecast to 2022 - Industry Insights by Type (Insulin ... P&S Market Research, the global insulin delivery device market ... is expected to grow at a CAGR of 6.6% ... is expected to witness the fastest growth at a ...
(Date:5/25/2016)... England , May 25, 2016 ... company employing the precision of circulating tumour DNA ... today announces the appointment of Professor Clive ... provide medical leadership across the clinical development programme, ... Inivata,s products help deliver significant improvements in clinical ...
(Date:5/24/2016)... 24, 2016   , ... in overall bowel cleansing and superiority in ... leansing of the ascending ... , Norgine B.V. today announced new positive data from ... ascorbate bowel preparation) versus standard 2 litre PEG with ascorbate. The ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through its Connor ... for the Tamika Catchings Legacy Tour that will commemorate the Indiana Fever ... basketball surfaces in all forms and levels of the game, Connor Sports has committed ...
(Date:5/26/2016)... , ... May 26, 2016 , ... The Woodlands ... offering a new model of care for living and healing, celebrated its grand ... Meaningful Life in a Real Home provided by Empowered Staff. , “This is an ...
(Date:5/26/2016)... ... ... There are nearly 14.5 million people living with and beyond cancer in the ... 2016, communities around the world will gather to recognize these cancer survivors as part ... is an annual worldwide Celebration of Life that is held on the first Sunday ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, the leading ... health and global clinical supply services, today announced two key appointments and the ... investment and strategic growth plans in the Asia Pacific region. , Howard Kim ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey ... , The 550 employees of Sun Health Senior Living (SHSL) may not ... reduces their doctor and prescription copays for the year, while holding the line on ...
Breaking Medicine News(10 mins):